Systemic Sclerosis

Robyn Domsic MD, MPH, reviews the treatment options for the cutaneous and pulmonary manifestations of systemic sclerosis.

Educational Objectives 

Upon completion of this activity, participants should be able to:

  • Recognize the clinical phenotypes / manifestations of systemic sclerosis for which immunosuppressive or anti-fibrotic therapy should be considered
  • Explain the literature to support the common use of medications to treat early diffuse SSc. Recognize agents currently undergoing investigational trial for this indication
  • Identify which medications are currently FDA approved or have orphan drug designation for the management of SSc-ILD
  • Explain the literature to support the use of cyclophosphamide, mycophenolate, nintedanib and tocilizumab for the treatment of SSc-related ILD 
  • Explain the stem cell transplant literature in SSc, and appreciate the often narrow window of therapeutic use

Disclosures

Dr. Domsic has financial interests with the following entity or entities producing health care goods or services as indicated below:

  • Consultant: Eicos Sciences Inc, Corbus Pharmaceutical Holdings, Formation Biologics

All presenters' disclosures of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients is listed above. No other planners, members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

For your credit transcript, please access our website four weeks postcompletion at http://ccehs.upmc.com and follow the link to the Credit Transcript page.

Release Date: 4/27/2021 | Last Modified On: 4/27/2021 | Expires: 4/27/2022